The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An update on the overall epidemiology, clinical characteristics, and outcomes from the COVID-19 and Cancer Consortium (CCC19).
 
Dimpy P Shah
No Relationships to Disclose
 
Pankil Shah
No Relationships to Disclose
 
Jeremy Lyle Warner
Stock and Other Ownership Interests - HemOnc.org
Consulting or Advisory Role - Flatiron Health; Melax Tech; Roche; Westat
 
Gerald Batist
Research Funding - Roche; Salpera
 
Christopher Ryan Friese
Research Funding - Merck (Inst); NCCN/Pfizer (Inst)
Other Relationship - National Cancer Institute; Patient-Centered Outcomes Research Institute (PCORI)
 
Elizabeth A. Griffiths
Honoraria - Novartis
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Genentech; Novartis; Otsuka; PicnicHealth; Taiho Oncology; Takeda
Research Funding - Apellis Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb/Celgene; Celgene (Inst); Celldex (Inst); Genentech (Inst)
 
Clara Hwang
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I)
Consulting or Advisory Role - EMD Serono; Genzyme; TEMPUS
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - AstraZeneca (Inst); Bausch Health (Inst); Bayer (Inst); Genentech (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
Kendra Vieira
No Relationships to Disclose
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sorrento Therapeutics; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Ruben A. Mesa
Consulting or Advisory Role - Constellation Pharmaceuticals; La Jolla Pharma; Novartis; Sierra Oncology
Research Funding - Abbvie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Genentech (Inst); Incyte (Inst); Mays Cancer Center (Inst); NCI (Inst); Promedior (Inst); Samus (Inst)
 
Matthew Puc
No Relationships to Disclose
 
Elizabeth M Robilotti
No Relationships to Disclose
 
Erika Ruiz-Garcia
Consulting or Advisory Role - Amgen; Bayer; BMS; Roche/Genentech
Travel, Accommodations, Expenses - Sanofi/Aventis
 
Andrew Jay Portuguese
No Relationships to Disclose
 
Andrew Lachlan Schmidt
Employment - EMD Serono/Merck (I)
Consulting or Advisory Role - Astellas Pharma
 
Lisa B. Weissmann
No Relationships to Disclose
 
Trisha Michel Wise-Draper
Stock and Other Ownership Interests - High Enroll
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - Caris Life Sciences; Exicure; Merck; Rakuten Medical; Shattuck Labs
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; GlaxoSmithKline; Janssen Oncology; Merck
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; bexion; Bristol-Myers Squibb; Caris Life Sciences; Caris Life Sciences; Lilly; Merck; Tesaro
 
Jill Barnholtz-Sloan
Stock and Other Ownership Interests - Surgical Management Professionals (I)
Consulting or Advisory Role - Medtronic (I); Monteris Medical (I)
Research Funding - Lentigen (I); Merck (I)
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Illumina (Inst); Imedex (Inst); medscape (Inst); MSD (Inst); Novartis (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Illumina (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; European Thoracic Oncology Platform (ETOP); Journal of Thoracic Oncology
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Genentech; Gilead Sciences; Guardant Health; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)